Advances in pharmacokinetics and pharmacodynamics of PD-1/PD-L1 inhibitors

Yan, Tao; Lun, Yu; Shangguan, Dangang; Li, Wei; Chen, Yun; Fu, Yilan; Tang, Jingyi; Liao, Dehua

doi:10.1016/j.intimp.2022.109638

Cited by 10 publications

(7 citation statements)

References 153 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Compared with chemotherapy, PD-1 inhibitors can further improve the anti-tumor immune response ability of patients while playing an indirect killing effect on tumor cells, with potent and sustained clinical response (19). Related studies have shown that PD-1 inhibitors validly increase the survival rate and prolong the survival of patients with advanced NSCLC, making them an important drug for the first-line treatment of advanced NSCLC (20). In recent years, anti-angiogenic drugs have attracted growing attention in the treatment of tumor diseases, as they can not only effectively improve the tumor microenvironment, but also further enhance the tumor immune response to increase the efficacy of tumor immunotherapy (21).…”

Section: Discussionmentioning

confidence: 99%

Effect of AGEs-RAGE system on the efficacy of PD-1 inhibitors in the treatment of driver-gene mutation negative advanced non-squamous non-small cell lung cancer

Xiangying Li,

Guan Wang,

Xiuye Sun

et al. 2023

Cell Mol Biol (Noisy-le-grand)

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Effect of AGEs-RAGE system on the efficacy of PD-1 inhibitors in the treatment of driver-gene mutation negative advanced non-squamous non-small cell lung cancer

Xiangying Li,

Guan Wang,

Xiuye Sun

et al. 2023

Cell Mol Biol (Noisy-le-grand)

View full text Add to dashboard Cite

“…In the real-world clinical setting, a treatment interval should exist between the initial treatment and ICI rechallenge. If the rechallenge is performed too soon, the ICIs from the initial treatment could still exist in the patients' blood circulation because some ICIs have long half-lives [123][124][125]. A sustained drug effect could keep tumor cells in a dormant state, and tumor progression was inhibited by immune mechanisms.…”

Section: Interval Between Two Ici Coursesmentioning

confidence: 99%

Current Status in Rechallenge of Immunotherapy

Hu,

Wang,

Jia

et al. 2023

Int. J. Biol. Sci.

View full text Add to dashboard Cite

The treatment of malignant tumors has entered the era of immunotherapy, and immune checkpoint inhibitors (ICIs) have brought significant benefits to patients. However, some patients are required to discontinue treatment with ICIs owing to factors such as disease progression and intolerable side effects. Faced with limited subsequent treatment options and complex medical needs, we searched PubMed, Embase, Cochrane library, and the NIH clinical trials database and found that ICI rechallenge could be a relevant clinical strategy. The factors that could affect the rechallenge efficacy include the patients' characteristics, therapeutic strategy selection, and the timing of treatment. Multiple factors are used to identify target population, of which clinical features and PD-L1 expression are more potential. Both single ICI rechallenge and combination therapy may have survival benefits. Patients who have tolerated initial immunotherapy well could undergo ICI rechallenge, while patients who have experienced grade 3 or higher immune-related adverse events should be carefully assessed prior to rechallenge. Interventions and the interval between two courses of ICI will clearly have an impact on the efficacy of subsequent treatment. Preliminary data evaluation supports further investigation on ICI rechallenge to identify the factors that could contribute to its efficacy.

show abstract

“…Since the release of nivolumab (36), the world's first PD-1 inhibitor, in 2014, 10 PD-1 inhibitors have been developed pembrolizumab (37), cemiplimab (38), toripalimab (39), sintilimab (40), camrelizumab (41), tislelizumab (42), penpulimab (43), prolgolimab (44), dostarlimab (45), and zimberelimab (46), and five PD-L1 inhibitors atezolizumab (47), durvalumab (48), avelumab (49), envafolimab (50), and sugemalimab (51) listed in succession. The Food and Drug Administration (FDA) has authorized six ICIs, whereas the National Medical Products Administration has approved 12 ICIs (NMPA) (52)(53)(54)(55).…”

Section: Antibody-based Pd-1/pd-l1 Inhibitorsmentioning

confidence: 99%

PD-1 and PD-L1: architects of immune symphony and immunotherapy breakthroughs in cancer treatment

Parvez,

Choudhary,

Mudgal

et al. 2023

Front. Immunol.

View full text Add to dashboard Cite

PD-1 (Programmed Cell Death Protein-1) and PD-L1 (Programmed Cell Death Ligand-1) play a crucial role in regulating the immune system and preventing autoimmunity. Cancer cells can manipulate this system, allowing them to escape immune detection and promote tumor growth. Therapies targeting the PD-1/PD-L1 pathway have transformed cancer treatment and have demonstrated significant effectiveness against various cancer types. This study delves into the structure and signaling dynamics of PD-1 and its ligands PD-L1/PD-L2, the diverse PD-1/PD-L1 inhibitors and their efficacy, and the resistance observed in some patients. Furthermore, this study explored the challenges associated with the PD-1/PD-L1 inhibitor treatment approach. Recent advancements in the combination of immunotherapy with chemotherapy, radiation, and surgical procedures to enhance patient outcomes have also been highlighted. Overall, this study offers an in-depth overview of the significance of PD-1/PD-L1 in cancer immunotherapy and its future implications in oncology.

show abstract

Advances in pharmacokinetics and pharmacodynamics of PD-1/PD-L1 inhibitors

Cited by 10 publications

References 153 publications

Effect of AGEs-RAGE system on the efficacy of PD-1 inhibitors in the treatment of driver-gene mutation negative advanced non-squamous non-small cell lung cancer

Effect of AGEs-RAGE system on the efficacy of PD-1 inhibitors in the treatment of driver-gene mutation negative advanced non-squamous non-small cell lung cancer

Current Status in Rechallenge of Immunotherapy

PD-1 and PD-L1: architects of immune symphony and immunotherapy breakthroughs in cancer treatment

Contact Info

Product

Resources

About